PentaPink Biotechnology Inc.

Pentapink develops therapeutic applications for novel, enzyme-resistant biopolymers

  • Pioneering the Next Generation of Biopolymer Therapeutics

    Developing intrinsically stable nucleic acids to revolutionize medicine through novel, enzyme-resistant platforms.

    Our Technology

    PentaPink Biotechnology is commercializing a revolutionary platform for synthesizing novel, enzyme-resistant oligonucleotides. Current RNA-based therapeutics are notoriously fragile, limiting their effectiveness and requiring complex delivery systems.

    Our proprietary methods create polymers that are intrinsically stable against enzymatic degradation, offering the potential for more effective and durable therapeutics. This breakthrough bypasses the need for costly chemical modifications, paving the way for a new class of safer and more accessible medicines for a wide range of diseases.

    Our Team


    Dr. Maikel Rheinstädter
    Co-Founder & CEO
    Professor of Biophysics, McMaster University
    maikel.rheinstadter@pentapinkbio.com

    Dr. Katherine Bujold
    Co-Founder & CSO
    Professor of Chemical Biology, McMaster University
    katherine.bujold@pentapinkbio.com


    Hannah Rheinstädter
    Co-Founder & COO
    Molecular Biology & Genetics, McMaster University
    hannah.rheinstadter@pentapinkbio.com

    Andrea Rheinstädter
    Co-Founder & CAO
    LL.M, Business Law
    andrea.rheinstadter@pentapinkbio.com